

PTO-90C (Rev. 2/95)



UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

Addr ss: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		IA AT	TORNEY DOCKET NO.
09/524,11	3 03/13/	00 PATEL	٠	J	6475.US.02
023492		HM12/010:	- -	Ε)	KAMINER
ABBOTT LABORATORIES			-	BAHAR, M	
DEPT. 377 - AP6D-2				ART UNIT	PAPER NUMBER
	T PARK ROA RK IL 6006			1617	
					01/03/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trad marks

	Application No.	Applicant(s)	
	09/524,113	PATEL ET AL.	
Office Action Summary	Examiner	Art Unit	
	Mojdeh Bahar	1617	
The MAILING DATE of this communication appe Period for Reply	ears on the cover sheet with the co	rrespondence address	
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION.	/ IS SET TO EXPIRE <u>1</u> MONTH(S) FROM	
 Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communi If the period for reply specified above is less than thirty (30) day be considered timely. If NO period for reply is specified above, the maximum statutory communication. Failure to reply within the set or extended period for reply will, b Status 	ication. is, a reply within the statutory minimum of period will apply and will expire SIX (6) I	thirty (30) days will MONTHS from the mailing date of this	
1) Responsive to communication(s) filed on			
2a) This action is FINAL . 2b) Th	is action is non-final.		
3) Since this application is in condition for alloward closed in accordance with the practice under			
Disposition of Claims			
4)⊠ Claim(s) <u>1-18</u> is/are pending in the application	l .		
4a) Of the above claim(s) is/are withdra	wn from consideration.		
5) Claim(s) is/are allowed.			
6) Claim(s) is/are rejected.			
7) Claim(s) is/are objected to.			
8) Claims 1-18 are subject to restriction and/or e	election requirement.		
Application Papers			
9) The specification is objected to by the Examine	er.		
10) The drawing(s) filed on is/are objected t	o by the Examiner.		
11) The proposed drawing correction filed on	_ is: a)□ approved b)□ disapp	proved.	
12) The oath or declaration is objected to by the Ex	xaminer.		
Priority under 35 U.S.C. § 119			
13) Acknowledgment is made of a claim for foreign	n priority under 35 U.S.C. § 119(a)-(d).	
a) ☐ All b) ☐ Some * c) ☐ None of the CERTIF		• • •	
1. received.	copies of the phone, december		
2. received in Application No. (Series Code	e / Serial Number)		
3. received in this National Stage application	on from the International Bureau ((PCT Rule 17.2(a)).	
* See the attached detailed Office action for a list	of the certified copies not receive	d.	
14) Acknowledgement is made of a claim for dome	estic priority under 35 U.S.C. & 11	9(e).	
Attachment(s)			
 15) Notice of References Cited (PTO-892) 16) Notice of Draftsperson's Patent Drawing Review (PTO-948) 17) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	19) Notice of Informati	ry (PTO-413) Paper No(s) Patent Application (PTO-152)	

Application/Control Number: 09/524,113

Art Unit: 1617

DETAILED ACTION

Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-15, drawn to a composition and delivery system comprising a lipid regulating agent dissolved or dispersed in at least one oil with one or more emulsifiers wherein the mixture is capable of forming an emulsion upon dilution with an aqueous phase, classified in Class 424, subclasses 455, 502 and Class 514 subclasses 460, 410, 510.
- II. Claims 16-18 drawn to a method of treating hyperlipidemia using a composition comprising a lipid regulating agent dissolved or dispersed in at least one oil with one or more emulsifiers wherein the mixture is capable of forming an emulsion upon dilution with an aqueous phase classified in Class 424, subclasses 455, 502 and Class 514 subclasses 460, 410, 510.

Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case, the process for treating hyperlipidemia can be practiced with another materially different product, e.g., Dextrothyroxine Sodium and Eldacimibe to name a few.

Because these inventions are distinct for the reasons given above and have

Application/Control Number: 09/524,113

Art Unit: 1617

acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that in order for the reply to this requirement to be complete it must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mojdeh Bahar whose telephone number is (703) 305-1007. The examiner can normally be reached on (703) 305-1007 from Monday to Friday from 9:00 a.m. to 5:00 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Minna Moezie, J.D., can be reached on (703) 308-4612. The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Mojdeh Bahar Patent Examiner Application/Control Number: 09/524,113

Art Unit: 1617

October 19, 2000

Page 4

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600